Peptide And Oligonucleotide CDMO Global Market Report 2026
상품코드:1957591
리서치사:The Business Research Company
발행일:On Demand Report
페이지 정보:영문 250 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
펩티드 및 올리고뉴클레오티드 CDMO 시장 규모는 최근 급성장하고 있습니다. 2025년 24억 2,000만 달러에서 2026년에는 27억 달러로 성장하여 CAGR은 11.9%를 나타낼 전망입니다. 지난 수년간의 성장에는 펩타이드 기반 치료제의 확대, 합성 올리고뉴클레오타이드의 복잡성 증가, 제약사의 자체 생산 능력의 한계, 규제 준수 요구 사항 증가, 안티센스 및 펩타이드 의약품의 조기 채택 등이 주요 요인으로 꼽힙니다.
펩티드 및 올리고뉴클레오티드 CDMO 시장 규모는 향후 몇 년간 급성장이 전망됩니다. 2030년에는 40억 3,000만 달러에 이르고, CAGR은 10.5%를 나타낼 전망입니다. 예측 기간의 성장 요인으로는 올리고뉴클레오티드 치료제 파이프라인 확대, 희귀질환 및 암 치료제 투자 증가, 신속한 임상시험 물질 생산에 대한 수요 증가, 전문 CDMO 파트너십에 대한 선호도 증가, 고체상합성 기술의 발전 등을 꼽을 수 있습니다. 예측 기간 동안 주요 동향으로는 펩타이드 및 올리고뉴클레오타이드 제조 아웃소싱 증가, CGMP를 준수하는 복잡한 분자 생산에 대한 수요 증가, 엔드투엔드 개발 및 제조 서비스 확대, 고효능 및 고순도 치료제에 대한 집중 강화, 확장 가능하고 유연한 제조 플랫폼 채택 확대 등을 들 수 있습니다. 확대 등을 들 수 있습니다.
개인 맞춤형 의료의 보급 확대는 향후 펩타이드 및 올리고뉴클레오티드 CDMO 시장의 성장을 가속할 것으로 예측됩니다. 맞춤형 의료는 유전적 요인, 환경, 생활습관 등 개인 특성에 따라 의료 선택과 치료법을 맞춤화하는 의료 전략입니다. 이러한 보급 확대는 유전체 분석 기술의 발전, 분자 수준에서의 질병 경로 규명, 환자의 고유한 유전적 배경과 건강 기록에 맞는 정밀하고 효과적인 치료법의 필요성 등 다양한 요인에 의해 촉진되고 있습니다. 펩타이드 및 올리고뉴클레오타이드 위탁 개발 및 제조 기관(CDMO)은 특정 환자 요건에 맞는 맞춤형 치료용 펩타이드 및 올리고뉴클레오타이드를 만드는 데 있어 이 분야에서 매우 중요한 역할을 담당하고 있습니다. 예를 들어, 2024년 2월 영국의 맞춤의료 추진 단체인 '맞춤의료연합'은 미국 식품의약국(FDA) 의약품평가연구센터(CDER)가 희귀질환 환자를 위한 16건의 신규 맞춤치료제를 승인했다고 발표했습니다. 이는 2022년 6건에서 크게 증가한 수치입니다. 이처럼 맞춤형 의료의 급격한 성장이 펩타이드 및 올리고뉴클레오티드 CDMO 시장의 확대를 견인하고 있습니다.
펩타이드 및 올리고뉴클레오티드 CDMO 시장의 주요 기업들은 서비스 포트폴리오 확대, 기술 전문성 강화, 시장 입지 확대를 위해 전략적 제휴를 우선적으로 추진하고 있습니다. 펩타이드 개발 및 생산 제휴는 펩타이드 기반 치료제의 창제 및 생산을 목적으로 하는 조직 간 협력 계약을 의미합니다. 예를 들어, 2023년 5월, 미국에 본사를 둔 위탁개발제조기관(CDMO)인 PolyPeptide Group AG는 독일 바이오테크 기업 Numaferm GmbH와 펩타이드 개발 및 생산에 있어 제휴를 맺었습니다. 이번 제휴를 통해 폴리펩타이드의 cGMP 제조 능력과 시장 도달 범위, 그리고 Numaferm의 친환경 펩타이드 제조 기술 및 생화학 플랫폼 기술을 활용할 수 있게 되었습니다. 이번 제휴는 유망한 펩타이드 후보물질의 공동개발을 핵심으로, 펩타이드 원료의약품(API)의 지속 가능한 생산을 실현하는 것을 목표로 합니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 공급망 분석
제4장 세계 시장 동향과 전략
제5장 최종 이용 산업 시장 분석
제6장 시장 : 금리, 인플레이션, 지정학, 무역 전쟁과 관세의 영향, 관세 전쟁과 무역 보호주의의 공급망에 대한 영향, 코로나 팬데믹이 시장에 미치는 영향을 포함한 거시경제 시나리오
제7장 세계 전략 분석 프레임워크, 현재 시장 규모, 시장 비교 및 성장률 분석
제8장 TAM(Total Addressable Market) 규모
제9장 시장 세분화
제10장 지역별/국가별 분석
제11장 아시아태평양 시장
제12장 중국 시장
제13장 인도 시장
제14장 일본 시장
제15장 호주 시장
제16장 인도네시아 시장
제17장 한국 시장
제18장 대만 시장
제19장 동남아시아 시장
제20장 서유럽 시장
제21장 영국 시장
제22장 독일 시장
제23장 프랑스 시장
제24장 이탈리아 시장
제25장 스페인 시장
제26장 동유럽 시장
제27장 러시아 시장
제28장 북미 시장
제29장 미국 시장
제30장 캐나다 시장
제31장 남미 시장
제32장 브라질 시장
제33장 중동 시장
제34장 아프리카 시장
제35장 시장 규제 상황과 투자환경
제36장 경쟁 구도와 기업 개요
제37장 기타 주요 기업 및 혁신 기업
제38장 세계 시장 경쟁 벤치마킹과 대시보드
제39장 주요 인수합병(M&A)
제40장 시장 잠재력이 높은 국가, 부문, 전략
제41장 부록
LSH
영문 목차
영문목차
A peptide and oligonucleotide CDMO (contract development and manufacturing organization) is a company offering services for the development, manufacturing, and supply of peptide- and oligonucleotide-based therapeutics. These organizations deliver specialized knowledge in synthetic chemistry, process development, analytical testing, and cGMP manufacturing to enable production of peptides and oligonucleotides for diverse clients.
The primary product categories for peptide and oligonucleotide CDMOs consist of peptides and oligonucleotides. Peptides are brief sequences of amino acids, generally under 50 in length, which serve key functions in biological activities like signaling and hormone control. They offer services including contract development and contract manufacturing. These find use in areas such as therapeutics, research tools, diagnostics, and more, serving end-users like biopharmaceutical firms, pharmaceutical companies, research institutions, academic and government bodies, and others.
Tariffs have affected the peptide and oligonucleotide CDMO market by increasing costs for imported raw materials, reagents, synthesis equipment, and specialized consumables used in manufacturing. These impacts are most pronounced in contract manufacturing services and therapeutic applications, particularly in regions dependent on cross-border chemical supply chains such as North America and Europe. Higher costs have pressured pricing and extended development timelines. However, tariffs have also encouraged localization of manufacturing, supplier diversification, and investments in domestic production capabilities.
The peptide and oligonucleotide cdmo market research report is one of a series of new reports from The Business Research Company that provides peptide and oligonucleotide cdmo market statistics, including peptide and oligonucleotide cdmo industry global market size, regional shares, competitors with a peptide and oligonucleotide cdmo market share, detailed peptide and oligonucleotide cdmo market segments, market trends and opportunities, and any further data you may need to thrive in the peptide and oligonucleotide cdmo industry. This peptide and oligonucleotide cdmo market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The peptide and oligonucleotide cdmo market size has grown rapidly in recent years. It will grow from $2.42 billion in 2025 to $2.7 billion in 2026 at a compound annual growth rate (CAGR) of 11.9%. The growth in the historic period can be attributed to growth in peptide-based therapeutics, increasing complexity of synthetic oligonucleotides, limited in-house manufacturing capabilities of drug developers, rising regulatory compliance requirements, early adoption of antisense and peptide drugs.
The peptide and oligonucleotide cdmo market size is expected to see rapid growth in the next few years. It will grow to $4.03 billion in 2030 at a compound annual growth rate (CAGR) of 10.5%. The growth in the forecast period can be attributed to expansion of oligonucleotide therapeutics pipelines, increasing investment in rare disease and oncology drugs, rising demand for rapid clinical trial material production, growing preference for specialized cdmo partnerships, advancements in solid-phase synthesis technologies. Major trends in the forecast period include rising outsourcing of peptide and oligonucleotide manufacturing, growing demand for cgmp-compliant complex molecule production, expansion of end-to-end development and manufacturing services, increased focus on high-potency and high-purity therapeutics, greater adoption of scalable and flexible manufacturing platforms.
The increasing uptake of personalized medicine is anticipated to fuel expansion in the peptide and oligonucleotide CDMO markets moving forward. Personalized medicine represents a healthcare strategy that customizes medical choices and therapies based on individual factors like genetics, environment, and lifestyle. This rising adoption stems from various drivers, including progress in genomic tools, deeper insights into molecular disease pathways, and the need for precise, effective treatments matched to patients' unique genetic backgrounds and health records. Peptide and oligonucleotide contract development and manufacturing organizations (CDMOs) are vital in this field, as they create bespoke therapeutic peptides and oligonucleotides suited to specific patient requirements. For example, in February 2024, the Personalized Medicine Coalition-a UK organization advocating for personalized medicine-noted that the FDA's Center for Drug Evaluation and Research (CDER) greenlit 16 new personalized therapies for rare disease patients, compared to just 6 in 2022. Thus, the surge in personalized medicine is propelling the peptide and oligonucleotide CDMO market.
Major companies in the peptide and oligonucleotide CDMO market are prioritizing strategic partnerships to improve their service portfolios, bolster technological expertise, and broaden market presence. Peptide development and production partnerships involve collaborative deals between organizations aimed at creating and producing peptide-based therapies. For example, in May 2023, PolyPeptide Group AG, a US-based contract development and manufacturing organization (CDMO), teamed up with Numaferm GmbH, a Germany-based biotech firm, for peptide development and production. This alliance leverages PolyPeptide's cGMP manufacturing capabilities and market reach alongside Numaferm's skills in eco-friendly peptide manufacturing and biochemical platforms. The collaboration centers on co-developing promising peptide candidates to enable more sustainable production of peptide-based APIs.
In May 2024, EUROAPI, a France-based contract development and manufacturing organization, acquired BianoGMP for an undisclosed sum. The deal aimed to strengthen EUROAPI's standing in the contract development and manufacturing organization (CDMO) market for oligonucleotides, building on its existing capacity in Frankfurt. BianoGMP, a Germany-based contract development and manufacturing organization (CDMO), specializes in analytical services for oligonucleotides.
Major companies operating in the peptide and oligonucleotide cdmo market are Thermo Fisher Scientific Inc., Merck KGaA, Ajinomoto Co. Inc., Lonza Group Ag, Wuxi Apptec Co. Ltd., Catalent Inc., Piramal Pharma Ltd, Curia Global Inc., Almac Group, Euroapi SA., CordenPharma International, Bachem Holding AG, Genscript Biotech Corporation, PolyPeptide Group, Rentschler Biopharma SE, Ambiopharm Inc, ScinoPharm, Senn Chemicals AG, Aurigene Pharmaceutical Services, Creative Peptides, Sylentis S.A.
North America was the largest region in the peptide and oligonucleotide CDMO market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the peptide and oligonucleotide cdmo market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the peptide and oligonucleotide cdmo market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The peptide and oligonucleotide CDMO market consists of revenues earned by entities by providing services such as analytical testing, oligonucleotide synthesis services, and regulatory support. The market value includes the value of related goods sold by the service provider or included within the service offering. The peptide and oligonucleotide CDMO market also includes sales of custom peptides and custom oligonucleotides. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Peptide And Oligonucleotide CDMO Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses peptide and oligonucleotide cdmo market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on end user analysis.
Benchmark performance against key competitors based on market share, innovation, and brand strength.
Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for peptide and oligonucleotide cdmo ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The peptide and oligonucleotide cdmo market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Scope
Markets Covered:1) By Product: Peptides; Oligonucleotides
2) By Service Type: Contract Development; Contract Manufacturing;
3) By Application: Therapeutics; Research Applications; Diagnostics; Other Applications
4) By End User: Biopharmaceutical Companies; Pharmaceutical Companies; Research Institutes; Academic and Government Organizations; Other End Users
Subsegments:
1) By Peptides: Active Pharmaceutical Ingredients (Apis); Peptide Drug Products; Peptide Synthesis And Manufacturing Services
2) By Oligonucleotides: Antisense Oligonucleotides; Sirna And Mrna Oligonucleotides; Oligonucleotide Synthesis And Manufacturing Services
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report
+ Excel Dashboard
Added Benefits
Bi-Annual Data Update
Customisation
Expert Consultant Support
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.
4.2.1 Rising Outsourcing Of Peptide And Oligonucleotide Manufacturing
4.2.2 Growing Demand For Cgmp-Compliant Complex Molecule Production
4.2.3 Expansion Of End-To-End Development And Manufacturing Services
4.2.4 Increased Focus On High-Potency And High-Purity Therapeutics
4.2.5 Greater Adoption Of Scalable And Flexible Manufacturing Platforms
5. Peptide And Oligonucleotide CDMO Market Analysis Of End Use Industries
5.1 Biopharmaceutical Companies
5.2 Pharmaceutical Companies
5.3 Research Institutes
5.4 Academic And Government Organizations
5.5 Clinical-Stage Biotechnology Companies
6. Peptide And Oligonucleotide CDMO Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market
7. Global Peptide And Oligonucleotide CDMO Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis
7.1. Global Peptide And Oligonucleotide CDMO PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
7.2. Global Peptide And Oligonucleotide CDMO Market Size, Comparisons And Growth Rate Analysis
7.3. Global Peptide And Oligonucleotide CDMO Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
7.4. Global Peptide And Oligonucleotide CDMO Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)
8. Global Peptide And Oligonucleotide CDMO Total Addressable Market (TAM) Analysis for the Market
8.1. Definition and Scope of Total Addressable Market (TAM)
8.2. Methodology and Assumptions
8.3. Global Total Addressable Market (TAM) Estimation
8.4. TAM vs. Current Market Size Analysis
8.5. Strategic Insights and Growth Opportunities from TAM Analysis
9. Peptide And Oligonucleotide CDMO Market Segmentation
9.1. Global Peptide And Oligonucleotide CDMO Market, Segmentation By Product, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Peptides, Oligonucleotides
9.2. Global Peptide And Oligonucleotide CDMO Market, Segmentation By Service Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Contract Development, Contract Manufacturing
9.3. Global Peptide And Oligonucleotide CDMO Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Therapeutics, Research Applications, Diagnostics, Other Applications
9.4. Global Peptide And Oligonucleotide CDMO Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Biopharmaceutical Companies, Pharmaceutical Companies, Research Institutes, Academic and Government Organizations, Other End Users
9.5. Global Peptide And Oligonucleotide CDMO Market, Sub-Segmentation Of Peptides, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Active Pharmaceutical Ingredients (Apis), Peptide Drug Products, Peptide Synthesis And Manufacturing Services
9.6. Global Peptide And Oligonucleotide CDMO Market, Sub-Segmentation Of Oligonucleotides, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Antisense Oligonucleotides, Sirna And Mrna Oligonucleotides, Oligonucleotide Synthesis And Manufacturing Services
10. Peptide And Oligonucleotide CDMO Market Regional And Country Analysis
10.1. Global Peptide And Oligonucleotide CDMO Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
10.2. Global Peptide And Oligonucleotide CDMO Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
11. Asia-Pacific Peptide And Oligonucleotide CDMO Market
11.1. Asia-Pacific Peptide And Oligonucleotide CDMO Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
11.2. Asia-Pacific Peptide And Oligonucleotide CDMO Market, Segmentation By Product, Segmentation By Service Type, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
12. China Peptide And Oligonucleotide CDMO Market
12.1. China Peptide And Oligonucleotide CDMO Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
12.2. China Peptide And Oligonucleotide CDMO Market, Segmentation By Product, Segmentation By Service Type, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
13. India Peptide And Oligonucleotide CDMO Market
13.1. India Peptide And Oligonucleotide CDMO Market, Segmentation By Product, Segmentation By Service Type, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
14. Japan Peptide And Oligonucleotide CDMO Market
14.1. Japan Peptide And Oligonucleotide CDMO Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
14.2. Japan Peptide And Oligonucleotide CDMO Market, Segmentation By Product, Segmentation By Service Type, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
15. Australia Peptide And Oligonucleotide CDMO Market
15.1. Australia Peptide And Oligonucleotide CDMO Market, Segmentation By Product, Segmentation By Service Type, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
16. Indonesia Peptide And Oligonucleotide CDMO Market
16.1. Indonesia Peptide And Oligonucleotide CDMO Market, Segmentation By Product, Segmentation By Service Type, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
17. South Korea Peptide And Oligonucleotide CDMO Market
17.1. South Korea Peptide And Oligonucleotide CDMO Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
17.2. South Korea Peptide And Oligonucleotide CDMO Market, Segmentation By Product, Segmentation By Service Type, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
18. Taiwan Peptide And Oligonucleotide CDMO Market
18.1. Taiwan Peptide And Oligonucleotide CDMO Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
18.2. Taiwan Peptide And Oligonucleotide CDMO Market, Segmentation By Product, Segmentation By Service Type, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
19. South East Asia Peptide And Oligonucleotide CDMO Market
19.1. South East Asia Peptide And Oligonucleotide CDMO Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
19.2. South East Asia Peptide And Oligonucleotide CDMO Market, Segmentation By Product, Segmentation By Service Type, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
20. Western Europe Peptide And Oligonucleotide CDMO Market
20.1. Western Europe Peptide And Oligonucleotide CDMO Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
20.2. Western Europe Peptide And Oligonucleotide CDMO Market, Segmentation By Product, Segmentation By Service Type, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
21. UK Peptide And Oligonucleotide CDMO Market
21.1. UK Peptide And Oligonucleotide CDMO Market, Segmentation By Product, Segmentation By Service Type, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
22. Germany Peptide And Oligonucleotide CDMO Market
22.1. Germany Peptide And Oligonucleotide CDMO Market, Segmentation By Product, Segmentation By Service Type, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
23. France Peptide And Oligonucleotide CDMO Market
23.1. France Peptide And Oligonucleotide CDMO Market, Segmentation By Product, Segmentation By Service Type, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
24. Italy Peptide And Oligonucleotide CDMO Market
24.1. Italy Peptide And Oligonucleotide CDMO Market, Segmentation By Product, Segmentation By Service Type, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
25. Spain Peptide And Oligonucleotide CDMO Market
25.1. Spain Peptide And Oligonucleotide CDMO Market, Segmentation By Product, Segmentation By Service Type, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
26. Eastern Europe Peptide And Oligonucleotide CDMO Market
26.1. Eastern Europe Peptide And Oligonucleotide CDMO Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
26.2. Eastern Europe Peptide And Oligonucleotide CDMO Market, Segmentation By Product, Segmentation By Service Type, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
27. Russia Peptide And Oligonucleotide CDMO Market
27.1. Russia Peptide And Oligonucleotide CDMO Market, Segmentation By Product, Segmentation By Service Type, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
28. North America Peptide And Oligonucleotide CDMO Market
28.1. North America Peptide And Oligonucleotide CDMO Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
28.2. North America Peptide And Oligonucleotide CDMO Market, Segmentation By Product, Segmentation By Service Type, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
29. USA Peptide And Oligonucleotide CDMO Market
29.1. USA Peptide And Oligonucleotide CDMO Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
29.2. USA Peptide And Oligonucleotide CDMO Market, Segmentation By Product, Segmentation By Service Type, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
30. Canada Peptide And Oligonucleotide CDMO Market
30.1. Canada Peptide And Oligonucleotide CDMO Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
30.2. Canada Peptide And Oligonucleotide CDMO Market, Segmentation By Product, Segmentation By Service Type, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
31. South America Peptide And Oligonucleotide CDMO Market
31.1. South America Peptide And Oligonucleotide CDMO Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
31.2. South America Peptide And Oligonucleotide CDMO Market, Segmentation By Product, Segmentation By Service Type, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
32. Brazil Peptide And Oligonucleotide CDMO Market
32.1. Brazil Peptide And Oligonucleotide CDMO Market, Segmentation By Product, Segmentation By Service Type, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
33. Middle East Peptide And Oligonucleotide CDMO Market
33.1. Middle East Peptide And Oligonucleotide CDMO Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
33.2. Middle East Peptide And Oligonucleotide CDMO Market, Segmentation By Product, Segmentation By Service Type, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
34. Africa Peptide And Oligonucleotide CDMO Market
34.1. Africa Peptide And Oligonucleotide CDMO Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
34.2. Africa Peptide And Oligonucleotide CDMO Market, Segmentation By Product, Segmentation By Service Type, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
35. Peptide And Oligonucleotide CDMO Market Regulatory and Investment Landscape
36. Peptide And Oligonucleotide CDMO Market Competitive Landscape And Company Profiles
36.1. Peptide And Oligonucleotide CDMO Market Competitive Landscape And Market Share 2024
36.1.1. Top 10 Companies (Ranked by revenue/share)
36.2. Peptide And Oligonucleotide CDMO Market - Company Scoring Matrix
36.2.1. Market Revenues
36.2.2. Product Innovation Score
36.2.3. Brand Recognition
36.3. Peptide And Oligonucleotide CDMO Market Company Profiles
36.3.1. Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis
36.3.2. Merck KGaA Overview, Products and Services, Strategy and Financial Analysis
36.3.3. Ajinomoto Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
36.3.4. Lonza Group AG Overview, Products and Services, Strategy and Financial Analysis
36.3.5. WuXi AppTec Co. Ltd. Overview, Products and Services, Strategy and Financial Analysis
37. Peptide And Oligonucleotide CDMO Market Other Major And Innovative Companies
